(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.41%) $78.43
(0.61%) $2.16
(0.57%) $2 321.70
(1.96%) $27.21
(-0.35%) $961.95
(-0.03%) $0.929
(-0.19%) $10.85
(-0.06%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 10.83%
@ $3.79
Issued: 14 Feb 2024 @ 13:46
Return: -8.71%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: -3.33 %
Live Chart Being Loaded With Signals
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma...
Stats | |
---|---|
Today's Volume | 1.19M |
Average Volume | 2.26M |
Market Cap | 417.21M |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-0.180 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.970 |
ATR14 | $0.00800 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Alleva Lawrence M | Buy | 3 996 | Stock Option (right to buy) |
2024-01-13 | Mandelia Ashish | Buy | 0 | |
2024-01-15 | Protopapas Anna | Buy | 17 708 | Common Stock |
2024-01-15 | Protopapas Anna | Buy | 21 250 | Common Stock |
2024-01-16 | Protopapas Anna | Sell | 29 399 | Common Stock |
INSIDER POWER |
---|
74.95 |
Last 98 transactions |
Buy: 4 017 838 | Sell: 585 969 |
Volume Correlation
Mersana Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
CSX | 0.929 |
FULC | 0.919 |
KYMR | 0.912 |
CNCR | 0.912 |
EOLS | 0.905 |
ALLO | 0.903 |
TARA | 0.903 |
RLMD | 0.902 |
ADAP | 0.901 |
SLN | 0.899 |
10 Most Negative Correlations | |
---|---|
SVOK | -0.889 |
RTPY | -0.883 |
RAAC | -0.871 |
VALN | -0.868 |
KVSB | -0.86 |
GHVI | -0.849 |
SPCB | -0.848 |
RELL | -0.844 |
AMTI | -0.841 |
MFNC | -0.837 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mersana Therapeutics Inc Correlation - Currency/Commodity
Mersana Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $36.86M |
Gross Profit: | $35.34M (95.88 %) |
EPS: | $-1.480 |
FY | 2023 |
Revenue: | $36.86M |
Gross Profit: | $35.34M (95.88 %) |
EPS: | $-1.480 |
FY | 2022 |
Revenue: | $26.58M |
Gross Profit: | $25.65M (96.51 %) |
EPS: | $-2.22 |
FY | 2021 |
Revenue: | $43 000.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.37 |
Financial Reports:
No articles found.
Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators